Maccura Biotechnology Co.Ltd (SHE:300463)
China · Delayed Price · Currency is CNY 9.45
+0.03 (0.32%)
Aug 11, 2026, 3:04 PM CST
SHE:300463 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 5,714 | 6,766 | 8,010 | 9,230 | 10,596 | 16,243 | |
Market Cap Growth | -25.41% | -15.53% | -13.22% | -12.89% | -34.77% | -37.43% |
Enterprise Value | 5,866 | 7,109 | 7,896 | 9,092 | 10,210 | 17,255 |
Last Close Price | 9.45 | 11.19 | 13.08 | 14.73 | 16.57 | 27.28 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | 63.17 | 29.53 | 14.96 | 16.98 |
Forward PE | 59.06 | 24.87 | 16.54 | 17.39 | 12.45 | 14.61 |
PS Ratio | 2.68 | 3.12 | 3.14 | 3.19 | 2.94 | 4.08 |
PB Ratio | 0.90 | 1.07 | 1.25 | 1.40 | 1.62 | 3.58 |
P/TBV Ratio | 0.98 | 1.16 | 1.35 | 1.55 | 1.80 | 3.98 |
P/FCF Ratio | 76.17 | - | - | 391.01 | - | 16.01 |
P/OCF Ratio | 8.16 | 11.23 | 12.64 | 10.24 | 12.57 | 10.05 |
PEG Ratio | - | 1.29 | 1.29 | 1.29 | 1.29 | 1.29 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 2.75 | 3.28 | 3.10 | 3.14 | 2.83 | 4.34 |
EV/EBITDA Ratio | 16.31 | 20.84 | 13.51 | 14.51 | 9.56 | 11.80 |
EV/EBIT Ratio | - | - | 30.12 | 27.42 | 12.52 | 13.91 |
EV/FCF Ratio | 78.20 | - | - | 385.18 | - | 17.00 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.15 | 0.15 | 0.10 | 0.10 | 0.11 | 0.25 |
Debt / EBITDA Ratio | 2.62 | 2.68 | 1.10 | 1.03 | 0.65 | 0.76 |
Debt / FCF Ratio | 12.54 | - | - | 28.18 | - | 1.10 |
Net Debt / Equity Ratio | 0.02 | 0.04 | -0.01 | -0.07 | -0.08 | 0.11 |
Net Debt / EBITDA Ratio | 0.36 | 0.67 | -0.13 | -0.77 | -0.51 | 0.33 |
Net Debt / FCF Ratio | 1.69 | -1.56 | 0.23 | -20.42 | 3.81 | 0.47 |
Asset Turnover | 0.27 | 0.27 | 0.32 | 0.36 | 0.49 | 0.62 |
Inventory Turnover | 1.01 | 1.09 | 1.32 | 1.42 | 1.62 | 1.62 |
Quick Ratio | 2.48 | 1.88 | 1.96 | 2.69 | 3.14 | 1.97 |
Current Ratio | 3.99 | 3.06 | 3.04 | 3.77 | 4.34 | 2.94 |
Return on Equity (ROE) | -0.76% | -0.65% | 1.82% | 4.64% | 12.68% | 23.45% |
Return on Assets (ROA) | -0.50% | -0.10% | 2.04% | 2.54% | 6.92% | 11.99% |
Return on Invested Capital (ROIC) | -0.97% | -0.20% | 4.00% | 5.46% | 13.19% | 21.52% |
Return on Capital Employed (ROCE) | -0.90% | -0.20% | 3.90% | 4.70% | 11.50% | 23.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -0.62% | -0.53% | 1.58% | 3.39% | 6.68% | 5.89% |
FCF Yield | 1.31% | -2.17% | -4.11% | 0.26% | -1.36% | 6.25% |
Dividend Yield | 1.10% | - | 0.80% | 1.04% | 2.11% | 1.73% |
Payout Ratio | - | - | 90.84% | 78.26% | 44.97% | 31.00% |
Buyback Yield / Dilution | 1.42% | 1.38% | -0.01% | -0.77% | -9.16% | 0.11% |
Total Shareholder Return | 2.52% | 1.38% | 0.78% | 0.28% | -7.05% | 1.83% |